Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Prostatic Neoplasms 12Carcinoma, Non-Small-Cell Lung 6Carcinoma, Hepatocellular 5Breast Neoplasms 5Lung Neoplasms 4Glioblastoma 4Neoplasms 3Myelodysplastic Syndromes 3Squamous Cell Carcinoma of Head and Neck 2Mycosis Fungoides 2Mouth Neoplasms 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Liver Neoplasms 2Leukemia, Myeloid, Acute 2Gliosarcoma 2Waldenstrom Macroglobulinemia 1Urinary Bladder Neoplasms 1Thrombosis 1Radiation Injuries 1Prostatic Neoplasms, Castration-Resistant 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neurofibrosarcoma 1Neurofibromatosis 1 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Mesothelioma, Malignant 1Meningioma 1

Interventions

lutetium Lu 177 dotatate 1X-Rays 1Specimen Handling 1Photons 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Lung Neuroendocrine Tumor × Photons × Clear all
NCT04665739 2026-05-13

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
70 enrolled
EndocrineNET

Advanced Lung Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡